It follows the dismissal of earlier charges against James and another longtime Trump foe, former FBI Director James Comey.
Revolution Medicines has recently advanced daraxonrasib, its oral multi-selective RAS(ON) inhibitor, into a Phase III trial for metastatic pancreatic ductal adenocarcinoma and, in June 2025, received ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback